Skip to main content
Premium Trial:

Request an Annual Quote

Bina Technologies Adds $1.75M to Series B Financing Round

NEW YORK (GenomeWeb News) – Bioinformatics company Bina Technologies added $1.75 million to its Series B financing round, bringing the total raised in the round to $8 million, it said today.

Bina previously announced it raised $6.25 million in the round in March.

The additional funding was led by Mohsen Moazami at Columbus Nova Technology Partners and Jerry Yang, the former Yahoo! co-founder and CEO who now runs his own personal venture firm called AME Cloud Ventures.

The new funds, the Redwood City, Calif.-based company said, will help move Bina in its goal of becoming an integrated genomic analysis platform company to "unlock the potential of DNA-based medicine and biotechnology by delivering fast, accurate, and scalable genomic analysis."

Proceeds from the earlier $6.25 million raise went toward expanding Bina's development, marketing, sales, and support infrastructure.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.